Susquehanna International Group
EYEGW

Susquehanna International Group’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

Susquehanna International Group’s Portfolio EYEGW Stock Details EYEGW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35,621
Closed -$2K – 11501
2020
Q2 		$2K Buy
35,621
+16,850
+90% +$733 ﹤0.01% 10018
2020
Q1 		$1K Sell
18,771
-1,947
-9% -$52 ﹤0.01% 10144
2019
Q4 		$1K Sell
20,718
-16,574
-44% -$559 ﹤0.01% 9602
2019
Q3 		$0 Buy
37,292
+2,010
+6% +$59 ﹤0.01% 11153
2019
Q2 		$0 Buy
35,282
+20,817
+144% +$702 ﹤0.01% 11142
2019
Q1 		$0 Sell
14,465
-32,179
-69% -$1.01K ﹤0.01% 10309
2018
Q4 		$1K Buy
+46,644
New +$2.42K ﹤0.01% 8814
2018
Q1 		– Sell
-12,900
Closed -$2K – 10586
2017
Q4 		$2K Hold
12,900
– – ﹤0.01% 9140
2017
Q3 		$2K Hold
12,900
– – ﹤0.01% 8715
2017
Q2 		$1K Hold
12,900
– – ﹤0.01% 9098
2017
Q1 		$2K Hold
12,900
– – ﹤0.01% 8806
2016
Q4 		$4K Buy
+12,900
New +$5.08K ﹤0.01% 9492

Susquehanna International Group's EYEGW Position: Q3 2020 in Review

Susquehanna International Group sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q3 2020, closing a stake of 35,621 shares — an estimated $2K sold.

Susquehanna International Group first reported a position in EYEGW in Q4 2016 and held it in 12 quarters. The position peaked at $4K in Q4 2016. 0 funds tracked by Wall St. Rank hold EYEGW as of Q3 2020.

  • Susquehanna International Group reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q3 2020 after selling out during the quarter.
  • Susquehanna International Group sold 35,621 Eyegate Pharmaceuticals, Inc. Warrants shares in Q3 2020, an estimated $2K.
  • Susquehanna International Group first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q4 2016 and held it in 12 quarters.
  • Susquehanna International Group's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $4K in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q3 2020.

Based on Susquehanna International Group's 13F filing for Q3 2020, filed 16 Nov 2020.